瑞舒伐他汀和血脂康治疗高脂血症的疗效观察  

Clinical effect of rosuvastatin and Xuezhikang on hyperlipidemia

作　　者：胡毅利 吴剑涓[2] 

机构地区：[1]天津市胸科医院,天津3000222 [2]天津市环湖医院,天津300060

出　　处：《天津药学》2014年第1期30-32,共3页Tianjin Pharmacy

摘　　要：观察瑞舒伐他汀、血脂康治疗高脂血症的临床疗效。方法:80例确认高脂血症患者随机分为两组,每组40例,分别予瑞舒伐他汀和血脂康治疗,观察8周,测定治疗前后的各项血脂指标,对其进行疗效评定,同时记录不良反应。结果:两组患者治疗后各项指标与治疗前比较,血清总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白(LDL-C)均有所下降,高密度脂蛋白(HDL-C)升高,差异有统计学意义(P<0.05),组间比较差异无统计学意义(P>0.05)。两组药物治疗均未见明显不良反应。结论:瑞舒伐他汀和血脂康均可显著降低血脂,且以LDL降低最为显著。治疗期间两组丙氨酸氨基转移酶(ALT)、尿素氮(BUN)、肌酐(Cr)和肌酸磷酸激酶(CK)水平均无明显变化,未见严重不良反应。Objective ： To observe the curative effect of rosuvastatin and Xuezhikang in the treatment of hyperlipidemia. Method ： Eighty subjects diagnosed with hyperlipidemia were randomly and divided into two groups, the rosuvastatin -treated group and the Xuezhikang - treated group. All the subjects were observed for eight weeks. The blood lipid indexes before and after treatment were measured to evaluate the curative effect. The adverse reactions were recorded in the meantime. Result ： Compared with the basline levels obtained prior to the treatment, TC,TG, LDL- C measured at the end of the treatment courese decreased, while HDL -C in- creased in both groups. The statistical difference was found between those indexes measured before and after the treatment （ P 〈 0.05 ） whereas there was no significant difference between the two groups （ P 〉 0.05 ）. No obvious adverse reaction to the drug treatment was observed. The ALT, BUN , Cr and CK levels had not significantly changed. Conclusion ： Rosuvastatin, Xuezhikang both can lower the blood lipids in patients with hyperlipidemia, especially the LDL index. During the treatment, and there is no se- vere adverse reaction.

关 键 词：高脂血症 瑞舒伐他汀 血脂康 

分 类 号：R972.6[医药卫生—药品]